A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)

Launched by CENTER FOR HUMAN REPRODUCTION · Jan 7, 2007

Keywords

ClinConnect Summary

Specific Aims:

The ability of women to respond to ovulation inducing medications also called ovarian reserve, declines with age. (Navot, Bergh et al. 1991; Scott, Leonardi et al. 1993; Toner and Flood 1993 ; Scott and Hofmann 1995; Scott 1996; ASRM 2002) When attempting in-vitro fertilization (IVF), older women produce few oocytes (Chuang, Chen et al. 2003; Orvieto, Bar-Hava et al. 2004) and yield few normal embryos, even when exposed to maximal gonadotropin stimulation.(Orvieto, Bar-Hava et al. 2004) As a result reproductive success for women over 40 years old is significantly reduced com...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women over the age of 40 and less than 45 years old presenting for IVF treatment.
• • Willingness to sign informed consent for study randomization.
• • Willingness to participate in 2 months pre-IVF treatment.
• Exclusion Criteria:
• • Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia.
• • Family history of significant genetic disease, or factor V Leiden thrombophilia.
• • Inability to present for monitoring visits.
• • Inability to follow medication instruction.